(Q34347608)

1 August 2017

title

Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). (English)

1 reference

polycystic ovary syndrome

1 August 2017

main subject

1 reference

1 reference

1 reference

Glueck CJ

1

1 reference

1 August 2017

Wang P

2

1 reference

1 August 2017

Fontaine R

3

1 reference

1 August 2017

Tracy T

4

1 reference

1 August 2017

Sieve-Smith L

5

1 reference

1 August 2017

publication date

1 September 2001

1 reference

Journal of Adolescent Health

1 August 2017

published in

1 reference

1 August 2017

volume

29

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

160-169

1 reference

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Endocrine features of polycystic ovary syndrome in a random population sample of 14-16 year old adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Menstrual disorders in adolescents. Excess androgens and the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Hormonal effects of flutamide in young women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Clinical assessment of body hair growth in women

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Polycystic ovary syndrome: a changing perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Endometrial carcinoma; ovarian dysfunction--a risk factor in young women

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Cardiovascular consequences of polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Contribution of fasting hyperinsulinemia to prediction of atherosclerotic cardiovascular disease status in 293 hyperlipidemic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Insulin sensitizing agents and polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1054-139X%2801%2900202-6

7 January 2021

10.1016/S1054-139X(01)00202-6

Identifiers

DOI

1 reference

1 August 2017

1 reference